Skip to main content
. 2023 Jan 4;41(8):1590–1599. doi: 10.1200/JCO.22.00940

FIG 4.

FIG 4.

Kaplan–Meier estimates of OS by MRD status (10–5) among patients in the ITT population. D-Rd, daratumumab, lenalidomide, and dexamethasone; ITT, intention-to-treat; MRD, minimal residual disease; OS, overall survival; Rd, lenalidomide and dexamethasone.